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Valid
Missing
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ode
ariance
kewness
td. Error of Skewness
urtosis
td. Error of Kurtosis
inimum
aximum
umObservations on the age, gender and the topographical location of
cancer on the body of affected patientsata source location University of Maiduguri Teaching hospital, Maiduguri, Borno state,
Northeast Nigeria.ata accessibility All the data are available this articleValue of the data
 The data is useful in the study of epidemiology of cancer in the affected areas.
 The data is an indication of the public health crisis in insurgency affected region in Nigeria.
 The data can be useful in cancer awareness, management and treatment.
 The data could be used in oncologic studies.
 The data can be used to test the performance of statistical models.1. Data
The data set represents the age, gender and topological (Top) location of cancer on the body of
cancer patients in the University of Maiduguri Teaching hospital located in Maiduguri, the capital of
Borno state, Nigeria.
The teaching hospital is the only tertiary health care facility in the state and often serves the other
northeast states like Yobe, Taraba, Adamawa, Bauchi and Gombe.
A total of 1671 patients were considered between the period of study and SPSS version 20 was
used to perform the analysis. The dataset is available as Supplementary data while a brief summary of
the data is presented in Table 1.
It was observed from Table 1 that information about the gender of a patient was not available,
hence the missing data of 1.
The frequency distribution of the gender of the patients is presented in Table 2.
The frequency distribution of the patients’ age is presented in Table 3.
The various parts of the body affected by cancer incidences and the number of people affected
(frequencies) are indicated in Table 4.
Table 4 shows that the part of the body affected mostly is the prostate gland. This is represented
graphically in Fig. 3.Gender Age Top
1670 1671 1671
1 0 0
1.53 50.06 37.59
2 60 5
0.249 281.086 816.431
−0.115 −0.258 0.241
0.060 0.060 0.060
−1.989 −0.220 −1.149
0.120 0.120 0.120
1 3 1
2 95 117
2553 83,658 62,806
Table 2
Frequency distribution of the patients’ gender.
Gender Frequency Percent Cumulative Percent
Valid Male 787 47.1 47.1
Female 883 52.8 100.0
Total 1670 99.9
Missing System 1 .1
Total 1671 100.0
Remark: Table 2 indicates that there are more female patients with cancer diseases than males. This is represented in a
pictorial form in Fig. 1.
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The data set was obtained from the patients’ records at the data center of the University of
Maiduguri teaching hospital. The hospital as stated earlier serves a large population from the six
Northeastern states of Nigeria and beyond. The Northeastern region in particular and the entire
northern region of the country is in variance with their natural endowments such as vast fertile lands,
rivers and lakes for irrigation, mineral resources and abundant sunshine for renewable energy. The
weak social structure of the region has resulted to excruciating poverty which often manifest as
homelessness and destitution, insurgency, violence and crime [1]. The region has high poverty index,
low human development index, lack of portable drinking water, electoral violence, dearth of medical
personnel, high mortality, low life expectancy, decayed infrastructure and also an epicenter for job-
lessness, underage and teenage pregnancy, female genital mutilation, epidemics, illiteracy, mal-
nutrition and now terrorism which comes in form of coordinated attacks on military, police forma-
tions and remote villages, guerrilla attacks, kidnappings, regicide, suicide bombings, mass killings,
abduction of school girls, extra-judicial killings and summary execution, hypnotizing and forced
conscriptions, indoctrination and forceful conversion to Islam and so on. The decadence is assumed to
be as a result of corruption, tribalism, military intervention in governance, inequality, mis-
appropriation, ﬁnancial recklessness, bankrupt of ideas and dearth of developmental agendas,
reduction of allocation of capital due to shortfalls of Nigeria revenue as a result of decline in crude oil
price. Globally, efforts towards improving the healthcare and reducing the incidence of cancer have
yielded desired results except in some developing countries. Hence, cancer related deaths remain
stubbornly high in those countries. Cancer awareness, screening, prevention, management, treatment
strategies are very low in the region/area studied in this article. Regrettably, capital allocations to the
health sector are inadequate and the available funds are often allegedly diverted by corrupt gov-
ernment ofﬁcials.
In addition, maternal death is one area that is currently affected by the Boko haram insurgency in
that region as reported by [2]. Moreover, other areas have been seriously affected; for example; food
security and dynamics, under ﬁve malnutrition, child mortality, escalation of cholera outbreaks,
infections, sexually transmitted diseases, unsafe birth practices and abortion, child prostitution, sex
for food at the displaced persons camps, increase in polio cases, See [3–8] for details. Some related
article can also be explored [9–31].
Next, we analyze the dataset collected using Chi-square test of independence and curve
estimation.
2.1. Chi-square test of independence
Chi-square test of independence was used to investigate the relationship between the location of
the cancer (top), gender and age of patients.
2.1.1. Test of independency between “Top” and gender of the patients
Hypothesis Testing I:
Table 3
Frequency distribution of the patient's age.
Age (years) Frequency Percent Cumulative Percent
3 6 0.4 0.4
4 5 0.3 0.7
5 1 0.1 0.7
6 5 0.3 1.0
7 5 0.3 1.3
8 2 0.1 1.4
9 1 0.1 1.5
10 2 0.1 1.6
12 4 0.2 1.9
14 4 0.2 2.1
15 8 0.5 2.6
16 6 0.4 2.9
17 4 0.2 3.2
18 9 0.5 3.7
19 6 0.4 4.1
20 15 0.9 5.0
22 9 0.5 5.5
23 12 0.7 6.2
24 11 0.7 6.9
25 17 1.0 7.9
26 11 0.7 8.6
27 15 0.9 9.5
28 19 1.1 10.6
29 7 0.4 11.0
30 51 3.1 14.1
31 6 0.4 14.4
32 22 1.3 15.7
33 7 0.4 16.2
34 10 0.6 16.8
35 74 4.4 21.2
36 16 1.0 22.1
37 15 0.9 23.0
38 27 1.6 24.7
39 13 0.8 25.4
40 94 5.6 31.1
41 13 0.8 31.8
42 18 1.1 32.9
43 15 0.9 33.8
44 11 0.7 34.5
45 74 4.4 38.9
46 18 1.1 40.0
47 13 0.8 40.8
48 32 1.9 42.7
49 11 0.7 43.3
50 134 8.0 51.3
51 12 0.7 52.1
52 23 1.4 53.4
53 19 1.1 54.6
54 23 1.4 56.0
55 94 5.6 61.6
56 26 1.6 63.1
57 18 1.1 64.2
58 19 1.1 65.4
59 7 0.4 65.8
60 161 9.6 75.4
61 9 0.5 75.9
62 13 0.8 76.7
63 9 0.5 77.3
64 8 0.5 77.7
65 82 4.9 82.6
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Table 3 (continued )
Age (years) Frequency Percent Cumulative Percent
66 6 0.4 83.0
67 10 0.6 83.6
68 16 1.0 84.6
69 2 0.1 84.7
70 128 7.7 92.3
71 5 0.3 92.6
72 8 0.5 93.1
73 4 0.2 93.4
74 3 0.2 93.5
75 26 1.6 95.1
76 5 0.3 95.4
77 5 0.3 95.7
78 6 0.4 96.1
79 2 0.1 96.2
80 36 2.2 98.3
81 1 0.1 98.4
82 1 0.1 98.4
83 1 0.1 98.5
84 2 0.1 98.6
85 13 0.8 99.4
86 2 0.1 99.5
90 6 0.4 99.9
93 1 0.1 99.9
95 1 0.1 100.0
Total 1671 100.0
Remarks: From Table 3, the lowest age captured is 3 years old while the oldest patient is 95 years old. The cancer diseases
affected both young and old but particularly, the age of the patients with highest number of cancer incidence is 60 years old.
This information is represented in Fig. 2.
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the patients.
Versus.
H1: There is a signiﬁcant association between the topological location of cancer and the gender of
the patients.
The result of the analysis is presented in Table 5.
The information about the correlation coefﬁcient and its corresponding p-value is presented in
Table 6.
2.1.2. Test of independency between “Top” and age of the patients
Hypothesis Testing II:
H0: There is no signiﬁcant association between topological location of cancer is not dependent on
the age of the patients.
Versus.
H1: There is a signiﬁcant association between topological location of cancer is dependent on the
age of the patients.
The result of the analysis is presented in Table 7.
Information about the correlation coefﬁcient and its corresponding p-value is presented in Table 8.2.2. Curve estimation
Linear, logarithmic, inverse, quadratic, cubic, power, growth, exponential and logistic regression
models were ﬁtted to the dataset. “Top” is the dependent variable while Age is the independent
variable. The summary of the variables used is presented in Table 9.
Table 4
Parts of the body affected by the various types of cancer.
Topological (Top) location of cancer Frequency Percent Cumulative Percent
Valid C77.9 Lymph node, NOS 9 0.5 0.5
C26.9 Gastrointestinal tract, NOS 9 0.5 1.1
C20.9 Rectum, NOS 54 3.2 4.3
C44.9 Skin, NOS 47 2.8 7.1
C61.9 Prostate gland 253 15.1 22.3
C63.9 Male genital organs, NOS 1 0.1 22.3
C49.6 Soft tissues of trunk 5 0.3 22.6
C50.9 Breast, NOS 92 5.5 28.1
C77.3 Lymph nodes of axilla or arm 2 0.1 28.2
C57.9 Female genital tract, NOS 15 0.9 29.1
C53.9 Cervix uteri 76 4.5 33.7
C22.0 Liver 31 1.9 35.5
C77.0 Lymph nodes of head, face and 6 0.4 35.9
C40.9 Bone of limb, NOS 4 0.2 36.1
C53.8 Overl. lesion of cervix uteri 1 0.1 36.2
C49.2 Soft tissues of lower limb an 7 0.4 36.6
C49.9 Other soft tissues 18 1.1 37.7
C67.9 Urinary bladder, NOS 32 1.9 39.6
C56.9 Ovary 60 3.6 43.2
C40.2 Long bones of lower limb 1 0.1 43.3
C44.2 External ear 1 0.1 43.3
C49.0 Soft tissues of head, face, & 9 0.5 43.9
C44.7 Skin of lower limb and hip 6 0.4 44.2
C39.9 Ill-deﬁned sites within resp 15 0.9 45.1
C49.1 Soft tissues of upper limb, s 4 0.2 45.4
C44.6 Skin of upper limb and shoulder 3 0.2 45.5
C19.9 Rectosigmoid junction 4 0.2 45.8
C64.9 Kidney, NOS 20 1.2 47.0
C40.8 Overl. lesion of bones of lim 1 0.1 47.0
C41.0 Bones of skull and face 2 0.1 47.2
C44.4 Skin of scalp and neck 6 0.4 47.5
C16.3 Gastric antrum 6 0.4 47.9
C18.0 Cecum 20 1.2 49.1
C16.9 Stomach, NOS 7 0.4 49.5
C49.5 Soft tissues of pelvis 3 0.2 49.7
C04.9 Floor of mouth, NOS 2 0.1 49.8
C73.9 Thyroid gland 14 0.8 50.6
C77.1 Intrathoracic lymph nodes 1 0.1 50.7
C52.9 Vagina, NOS 8 0.5 51.2
C10.2 Lateral wall of oropharynx 1 0.1 51.2
C44.5 Skin of trunk 2 0.1 51.3
C69.0 Conjunctiva 14 0.8 52.2
C21.8 Overl. lesion rectum, anal ca 9 0.5 52.7
C49.4 Soft tissues of abdomen 4 0.2 53.0
C18.4 Transverse colon 1 0.1 53.0
C41.9 Bone, NOS 1 0.1 53.1
C76.2 Abdomen, NOS 1 0.1 53.1
C76.5 Lower limb, NOS 1 0.1 53.2
C69.6 Orbit, NOS 1 0.1 53.3
C49.3 Soft tissues of thorax 3 0.2 53.4
C55.9 Uterus, NOS 30 1.8 55.2
C44.8 Overl. lesion of skin 1 0.1 55.3
C51.9 Vulva, NOS 1 0.1 55.4
C10.9 Oropharynx, NOS 2 0.1 55.5
C30.1 Middle ear 1 0.1 55.5
C62.9 Testis, NOS 2 0.1 55.7
C15.0 Cervical esophagus 12 0.7 56.4
C18.7 Sigmoid colon 1 0.1 56.4
C80.9 Unknown primary site 200 12.0 68.4
C77.2 Intra-abdominal lymph nodes 1 0.1 68.5
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Table 4 (continued )
Topological (Top) location of cancer Frequency Percent Cumulative Percent
C11.9 Nasopharynx, NOS 3 0.2 68.6
C50.0 Nipple 168 10.1 78.7
C53.0 Endocervix 105 6.3 85.0
C53.1 Exocervix 1 0.1 85.0
C67.4 Posterior wall of urinary bla 8 0.5 85.5
C16.0 Cardia, NOS 33 2.0 87.5
C21.0 Anus, NOS 17 1.0 88.5
C51.0 Labium majus 3 0.2 88.7
C67.0 Trigone of urinary bladder 57 3.4 92.1
C44.0 Skin of lip, NOS 15 0.9 93.0
C11.0 Superior wall of nasopharynx 16 1.0 94.0
C08.0 Submandibular gland 3 0.2 94.1
C14.0 Pharynx, NOS 5 0.3 94.4
C26.0 Intestinal tract, NOS 7 0.4 94.9
C65.9 Renal pelvis 4 0.2 95.1
C10.0 Vallecula 6 0.4 95.5
C25.0 Head of pancreas 5 0.3 95.8
C60.0 Prepuce 4 0.2 96.0
C21.2 Cloacogenic zone 4 0.2 96.2
C18.6 Descending colon 1 0.1 96.3
C66.9 Ureter 1 0.1 96.3
C50.1 Central portion of breast 1 0.1 96.4
C34.0 Main bronchus 1 0.1 96.5
C21.1 Anal canal 3 0.2 96.6
C18.9 Colon, NOS 1 0.1 96.7
C01.9 Base of tongue, NOS 3 0.2 96.9
C62.0 Undescended testis 4 0.2 97.1
C11.2 Lateral wall of nasopharynx 1 0.1 97.2
C50.6 Axillary tail of breast 1 0.1 97.2
C54.1 Endometrium 2 0.1 97.4
C25.9 Pancreas, NOS 1 0.1 97.4
C30.0 Nasal cavity 1 0.1 97.5
C00.9 Lip, NOS 1 0.1 97.5
C54.2 Myometrium 1 0.1 97.6
C48.8 Overl. lesion of retroperiton 1 0.1 97.7
C76.7 Other ill-deﬁned sites 1 0.1 97.7
C03.0 Upper gum 2 0.1 97.8
C15.9 Oesophagus, NOS 1 0.1 97.9
C69.9 Eye, NOS 1 0.1 98.0
C16.4 Pylorus 1 0.1 98.0
C07.9 Parotid gland 2 0.1 98.1
C67.5 Bladder neck 1 0.1 98.2
C57.4 Uterine adnexa 1 0.1 98.3
C16.2 Body of stomach 1 0.1 98.3
C13.0 Postcricoid region 7 0.4 98.7
C37.9 Thymus 1 0.1 98.8
C17.0 Duodenum 1 0.1 98.9
C06.0 Cheek mucosa 1 0.1 98.9
C04.0 Anterior ﬂoor of mouth 4 0.2 99.2
C47.0 Per. nerves & A.N.S. of head, 3 0.2 99.3
C09.0 Tonsillar fossa 2 0.1 99.5
C38.4 Pleura, NOS 1 0.1 99.5
C38.0 Heart 4 0.2 99.8
C67.1 Dome of urinary bladder 1 0.1 99.8
C22.1 Intrahepatic bile duct 1 0.1 99.9
C76.0 Head, face or neck, NOS 1 0.1 99.9
C23.9 Gallbladder 1 0.1 100.0
Total 1671 100.0
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Fig. 1. Gender of the patients.
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The summary of the simple linear regression model is presented in Table 10.
The corresponding analysis of variance (ANOVA) table testing for the ﬁtness of the model is
presented in Table 11.
The linear regression model is signiﬁcant at 0.05 level of signiﬁcance and with R-square value of 3%.
2.2.2. Logarithmic model
The summary of the logarithmic model is presented in Table 12.
Estimating the model parameter gives the result in Table 13.
The ANOVA table for the logarithmic model is presented in Table 14.
The logarithmic model is signiﬁcant at 0.05 level of signiﬁcance and with R-square value of 1.7%.
2.2.3. Inverse model
The summary of the inverse model is presented in Table 15.
The result for the estimation of parameters using the inverse model is presented in Table 16.
The corresponding ANOVA table is presented in Table 17.
The inverse model is not signiﬁcant as its p-value is greater than the level of signiﬁcance (0.05).
2.2.4. Quadratic model
The summary for the quadratic model is presented in Table 18.
The result for the estimation of parameter using the quadratic model is presented in Table 19.
The corresponding ANOVA table is presented in Table 20.
The quadratic model is signiﬁcant at 0.05 level of signiﬁcance and with R-square value of 3.8%.
2.2.5. Cubic model
The summary for the cubic model is presented in Table 21.
The result for the estimation of parameter for the cubic model is presented in Table 22.
The corresponding ANOVA table is presented in Table 23.
Fig. 2. Age of the patients.
Fig. 3. Diagrammatic presentation of the parts of the body affected by cancer.
P.I. Adamu et al. / Data in Brief 18 (2018) 2029–2046 2037The cubic model is signiﬁcant and with R-square value of 3.9%.2.2.6. Power model
The summary for the power model is presented in Table 24.
The result for the estimation of parameter for the power model is presented in Table 25.
The corresponding ANOVA table is presented in Table 26.
Table 5
Result of the chi-square test between gender and “Top”.
Chi-Square Tests Value df Asymp. Sig. (2-sided)
Pearson Chi-Square 928.735 116 0.000
Likelihood Ratio 1214.083 116 0.000
Linear-by-Linear Association 64.659 1 0.000
N of Valid Cases 1670
Remarks: The null hypothesis (H0) is rejected since the p-value (0.000) is less than the level of signiﬁcance (0.05). Therefore, it
can be concluded that there is a signiﬁcant association between the topological location of cancer and the gender of the
patients.
Table 6
Correlation coefﬁcient.
Symmetric Measures Value Asymp. Std. Error Approx. T Approx. Sig.
Interval by Interval Pearson's R 0.197 0.024 8.199 0.000
Ordinal by Ordinal Spearman Correlation 0.253 0.024 10.661 0.000
N of Valid Cases 1670
Table 7
Result of the chi-square test between age and “Top”.
Chi-Square Tests Value Df Asymp. Sig. (2-sided)
Pearson Chi-Square 10762.735 9628 0.000
Likelihood Ratio 3148.516 9628 1.000
Linear-by-Linear Association 50.758 1 0.000
N of Valid Cases 1671
Remarks: Since the p-value is also less than 0.05, we conclude that there is a signiﬁcant association between the topological
location of cancer and the age of the patients.
Table 8
Correlation coefﬁcient result.
Symmetric Measures Value Asymp. Std. Error Approx. T Approx. Sig.
Interval by Interval Pearson's R −.174 0.024 −7.233 0.000
Ordinal by Ordinal Spearman Correlation −.189 0.025 −7.881 0.000
N of Valid Cases 1671
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2.2.7. Growth model
The model summary for the growth model is presented in Table 27.
The result for the estimation of parameter of the growth model is presented in Table 28.
The corresponding ANOVA table is presented in Table 29.
The growth model is signiﬁcant at 0.05 level of signiﬁcance and with R-square value of 4.7%.
2.2.8. Exponential model
The model summary for the exponential model is presented in Table 30.
The result for the estimation of parameter for the exponential model is presented in Table 31.
Table 9
Summary of the variables.
Variable Processing Summary Variables
Dependent Independent
Top Age
Number of Positive Values 1671 1671
Number of Zeros 0 0
Number of Negative Values 0 0
Number of Missing Values User-Missing 0 0
System-Missing 0 0
Table 10
Model summary.
R R Square Adjusted R Square Std. Error of the Estimate
0.174 0.030 0.030 28.144
The independent variable is Age.
Table 11
ANOVA table for the linear model.
ANOVA
Sum of Squares df Mean Square F Sig.
Regression 41440.679 1 41440.679 52.318 0.000
Residual 1321998.748 1669 792.090
Total 1363439.427 1670
The independent variable is Age.
Table 12
Model summary for the logarithmic model.
R R Square Adjusted R Square Std. Error of the Estimate
0.130 0.017 0.016 28.340
The independent variable is Age.
Table 13
Parameter estimation for the logarithmic model.
Coefﬁcients Unstandardized Coefﬁcients Standardized
Coefﬁcients
T Sig.
B Std. Error Beta
ln(Age) −8.130 1.520 −0.130 −5.349 0.000
(Constant) 68.755 5.869 11.716 0.000
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The exponential model is signiﬁcant at 0.05 level of signiﬁcance and with R-square value of 4.7%.
2.2.9. Logistic model
The model summary for the logistic model is presented in Table 33.
The estimation of parameters for the logistic model is presented in Table 34.
Table 14
ANOVA table for the logarithmic model.
ANOVA
Sum of Squares df Mean Square F Sig.
Regression 22977.216 1 22977.216 28.609 0.000
Residual 1340462.210 1669 803.153
Total 1363439.427 1670
The independent variable is Age.
Table 15
Summary of the inverse model.
R R Square Adjusted R Square Std. Error of the Estimate
0.047 0.002 0.002 28.550
The independent variable is age.
Table 16
Parameter estimation using inverse model.
Coefﬁcients Unstandardized Coefﬁcients Standardized Coefﬁcients t Sig.
B Std. Error Beta
1/Age 49.544 25.664 0.047 1.930 0.054
(Constant) 36.327 0.956 38.018 0.000
Table 17
The ANOVA table for the inverse model.
ANOVA
Sum of Squares df Mean Square F Sig.
Regression 3037.719 1 3037.719 3.727 0.054
Residual 1360401.707 1669 815.100
Total 1363439.427 1670
The independent variable is age.
Table 18
Summary for the quadratic model.
R R Square Adjusted R Square Std. Error of the Estimate
0.195 0.038 0.037 28.043
The independent variable is age.
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The logistic model is also signiﬁcant at 0.05 level of signiﬁcance and with R-square value of 4.7%.
Lastly, all the ﬁtted models are illustrated in Fig. 4.
Table 19
Parameter estimation for the quadratic model.
Coefﬁcients Unstandardized Coefﬁcients Standardized
Coefﬁcients
t Sig.
B Std. Error Beta
Age 0.348 0.183 0.204 1.897 0.058
Age ** 2 −0.007 0.002 −0.388 −3.607 0.000
(Constant) 38.929 4.329 8.992 0.000
Table 20
ANOVA table for the quadratic model.
ANOVA
Sum of Squares df Mean Square F Sig.
Regression 51674.289 2 25837.144 32.854 0.000
Residual 1311765.138 1668 786.430
Total 1363439.427 1670
The independent variable is age.
Table 21
Summary for the cubic model.
R R Square Adjusted R Square Std. Error of the Estimate
0.197 0.039 0.037 28.036
The independent variable is age.
Table 22
Parameter estimation for the cubic model.
Coefﬁcients Unstandardized Coefﬁcients Standardized Coefﬁcients t Sig.
B Std. Error Beta
Age 0.951 0.477 0.558 1.993 0.046
Age ** 2 −0.021 0.011 −1.230 −1.970 0.049
Age ** 3 0.000 0.000 0.504 1.369 0.171
(Constant) 32.108 6.601 4.864 0.000
Table 23
ANOVA table for the cubic model.
ANOVA
Sum of Squares df Mean Square F Sig.
Regression 53146.668 3 17715.556 22.538 0.000
Residual 1310292.759 1667 786.018
Total 1363439.427 1670
The independent variable is age.
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Table 24
Summary for the power model.
R R Square Adjusted R Square Std. Error of the Estimate
0.159 0.025 0.025 1.125
The independent variable is age.
Table 25
Parameter estimation for the power model.
Coefﬁcients Unstandardized Coefﬁcients Standardized Coefﬁcients t Sig.
B Std. Error Beta
ln(Age) −0.397 0.060 −0.159 −6.583 0.000
(Constant) 105.955 24.692 4.291 0.000
The dependent variable is ln(Top).
Table 26
ANOVA table for the power model.
ANOVA
Sum of Squares df Mean Square F Sig.
Regression 54.875 1 54.875 43.330 0.000
Residual 2113.710 1669 1.266
Total 2168.585 1670
The independent variable is age.
Table 27
Summary for the growth model.
R R Square Adjusted R Square Std. Error of the Estimate
0.216 0.047 0.046 1.113
The independent variable is age.
Table 28
Parameter estimation for the growth model.
Coefﬁcients Unstandardized Coefﬁcients Standardized Coefﬁcients t Sig.
B Std. Error Beta
Age −0.015 0.002 −0.216 −9.038 0.000
(Constant) 3.875 0.086 45.180 0.000
The dependent variable is ln(Top).
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Table 29
ANOVA table for the growth model.
ANOVA
Sum of Squares df Mean Square F Sig.
Regression 101.181 1 101.181 81.683 0.000
Residual 2067.404 1669 1.239
Total 2168.585 1670
The independent variable is age.
Table 30
Summary for the exponential model.
R R Square Adjusted R Square Std. Error of the Estimate
0.216 0.047 0.046 1.113
The independent variable is age.
Table 31
Parameter estimation for the exponential model.
Coefﬁcients Unstandardized Coefﬁcients Standardized Coefﬁcients t Sig.
B Std. Error Beta
Age −0.015 0.002 −0.216 −9.038 0.000
(Constant) 48.173 4.132 11.660 0.000
The dependent variable is ln(Top).
Table 32
ANOVA table for the exponential model.
ANOVA
Sum of Squares df Mean Square F Sig.
Regression 101.181 1 101.181 81.683 0.000
Residual 2067.404 1669 1.239
Total 2168.585 1670
The independent variable is age.
Table 33
Summary for the logistic model.
R R Square Adjusted R Square Std. Error of the Estimate
0.216 0.047 0.046 1.113
The independent variable is age.
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Table 34
Parameter estimation for the logistic model.
Coefﬁcients Unstandardized Coefﬁcients Standardized Coefﬁcients t Sig.
B Std. Error Beta
Age 1.015 0.002 1.241 615.592 0.000
(Constant) 0.021 0.002 11.660 0.000
The dependent variable is ln(1 / Top).
Table 35
ANOVA table for the logistic model.
ANOVA
Sum of Squares df Mean Square F Sig.
Regression 101.181 1 101.181 81.683 0.000
Residual 2067.404 1669 1.239
Total 2168.585 1670
The independent variable is age.
Fig. 4. The ﬁtted model with respect to the data set.
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 More females are infected with cancer than men.
 The age with the highest record (or incidence) of cancer is 60 years old.
 The part of the body that is mostly affected by cancer is the prostate gland (based on the data set
collected).
 There is a signiﬁcant association between the topological location of cancer and the gender of the
patients.
 There is a signiﬁcant association between the topological location of cancer and the age of the
patients.
 All the models ﬁtted to the data produced low R-square values; nevertheless, the models that best
ﬁt the data based on their R-square values are growth model, exponential model and logistic
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